For the year ending 2025-12-31, LYRA has $36,108K in assets. $46,825K in debts. $15,893K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 15,893 | |||
| Prepaid expenses and other current assets | 379 | |||
| Total current assets | 16,272 | |||
| Total | 5,600 | |||
| Accumulated depreciation | 4,549 | |||
| Property and equipment, net | 1,051 | |||
| Operating lease right-of-use assets | 16,792 | |||
| Restricted cash | 1,993 | |||
| Total assets | 36,108 | |||
| Accounts payable | 663 | |||
| Restructuring liability | 3,266 | |||
| Accrued expenses and other current liabilities | 775 | |||
| Operating lease liabilities | 4,818 | |||
| Total current liabilities | 9,522 | |||
| Operating lease liabilities, net of current portion | 25,441 | |||
| Deferred revenue, net of current portion | 11,862 | |||
| Total liabilities | 46,825 | |||
| Common stock, 0.001 par value 200,000,000 shares authorized at december 31, 2025 and 2024 1,774,882 and 1,310,308 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 2 | |||
| Additional paid-in capital | 422,990 | |||
| Accumulated deficit | -433,709 | |||
| Total stockholders' (deficit) equity | -10,717 | |||
| Total liabilities and stockholders' (deficit) equity | 36,108 | |||
Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc. (LYRA)